The Valley Desk

NCT06407934 · Interventional trial

A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

Overall registry status Active not recruiting

Phase 3

Conditions Dermatitis Atopic

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov